| Interethnic Variability in CYP2D6, CYP2C9, and CYP2C19 Genes and Predicted Drug Metabolism Phenotypes Among 6060 Ibero- and Native Americans: RIBEF … MEG Naranjo, F Rodrigues-Soares, EM Penas-Lledo, E Tarazona-Santos, ... Omics: a journal of integrative biology 22 (9), 575-588, 2018 | 41 | 2018 |
| Genomic Ancestry, CYP2D6, CYP2C9, and CYP2C19 Among Latin Americans F Rodrigues‐Soares, EM Peñas‐Lledó, E Tarazona‐Santos, ... Clinical Pharmacology & Therapeutics 107 (1), 257-268, 2020 | 31 | 2020 |
| Losartan hydroxylation phenotype in an Ecuadorian population: influence of CYP2C9 genetic polymorphism, habits and gender P Dorado, LJ Beltrán, E Machin, EM Penas-LLedo, E Terán, A LLerena, ... Pharmacogenomics 13 (15), 1711-1717, 2012 | 27 | 2012 |
| Pharmacogenetics in Central American healthy volunteers: interethnic variability C Céspedes-Garro, MEG Naranjo, R Ramírez, V Serrano, H Fariñas, ... Drug Metabolism and Personalized Therapy 30 (1), 19-31, 2015 | 23 | 2015 |
| CYP2D6 -1584C>G promoter polymorphism and debrisoquine ultrarapid hydroxylation in healthy volunteers A LLerena, P Dorado, R Ramírez, LR Calzadilla, E Penas-LLedo, ... Pharmacogenomics 14 (16), 1973-1977, 2013 | 23 | 2013 |
| Characterization of CYP2D6 genotypes and metabolic profiles in the Portuguese population: pharmacogenetic implications J Albuquerque, C Ribeiro, MEG Naranjo, A Llerena, M Grazina Personalized Medicine 10 (7), 709-718, 2013 | 16 | 2013 |
| Pharmacogenetics in Latin American populations: regulatory aspects, application to herbal medicine, cardiovascular and psychiatric disorders I Rodeiro, D Remírez-Figueredo, M García-Mesa, P Dorado, A LLerena, ... Walter de Gruyter 27 (1), 57-60, 2012 | 16 | 2012 |
| Evaluation of drug-metabolizing enzyme hydroxylation phenotypes in Hispanic populations: the CEIBA cocktail F De Andrés, M Sosa-Macías, BP Lazalde-Ramos, MEG Naranjo, ... Drug metabolism and drug interactions 28 (3), 135-146, 2013 | 14 | 2013 |
| Development of a HPLC method for the determination of losartan urinary metabolic ratio to be used for the determination of CYP2C9 hydroxylation phenotypes P Dorado, E Machín, F de Andrés, MEG Naranjo, EM Peñas-Lledó, ... Drug Metabolism and Drug Interactions 27 (4), 217-223, 2012 | 12 | 2012 |
| Eating disorder symptoms and CYP2D6 variation in Cuban healthy females: a report from the Ibero-American Network of Pharmacogenetics E M Penas-LLedo, I González, P Dorado, B Pérez, L R Calzadilla, ... Current Pharmacogenomics and Personalized Medicine (Formerly Current …, 2012 | 4 | 2012 |
| Estudio del polimorfismo del citocromo 2d6 en una población colombiana AR Borbón Orjuela Pontificia Universidad Javeriana, 2009 | 1 | 2009 |
| High prevalence of CYP2D6 ultrarapid metabolizers in a mestizo Colombian population in relation to Hispanic mestizo populations A P Sarmiento, P Dorado, A Borbón, F de Andrés, A LLerena, ... Pharmacogenomics 21 (17), 1227-1236, 2020 | | 2020 |
| Calidad de vida en cuidadores de pacientes con virus de inmunodeficiencia adquirida VIH. CJ Avendaño Vásquez, AR Borbón Orjuela, L Gallego Bohórquez Universidad Sergio Arboleda, 2013 | | 2013 |
